^
Association details:
| Biomarker: | NRAS Q61 |
|---|---|
| Cancer: | Melanoma |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) + lifirafenib (BGB-283) (EGFR inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vertical inhibition of the MAPK pathway as potential treatment strategy in NRAS-mutant melanoma
Published date:
10/12/2022
Excerpt:
The combinatorial effects of mirdametinib with the pan-RAF dimer inhibitor lifirafenib or BGB-3245 were evaluated in a cohort of 14 primary and patient-derived melanoma cell lines harboring NRAS Q61 mutations....Results from this study showed significant therapeutic effects on NRAS Q61 mutated melanoma cell lines through combination of mirdametinib with either pan-RAF inhibitor both in vitro and in vivo….NRAS Q61 may serve as a prospective biomarker for patient stratification in trials assessing the combination of MEK and pan-RAF inhibitors in mutant melanoma.
